BLUE BELL, Pa., July 1, 2011 /PRNewswire/ — Inovio
Pharmaceuticals, Inc. (NYSE Amex:
INO), a leader in the development of therapeutic and preventive
vaccines against cancers and infectious diseases, announced today
that Dr. Avtar Dhillon has become non-executive Chairman of the
Board of Directors. Dr. Dhillon was initially appointed as
Executive Chairman of the Board in 2009 in conjunction with the
merger between Inovio Biomedical and VGX Pharmaceuticals with a
mandate to provide continuity and strategic guidance during their
integration. Dr. Dhillon will now exclusively focus on his role as
chairman of the Board of Directors and will no longer have
executive responsibilities.

Dr. J. Joseph Kim, Inovio’s President and CEO, said: “Avtar has
provided strong leadership and support during the integration and
build up of Inovio Pharmaceuticals. We look forward to his
continued leadership as a non-executive Chairman.”  

About Inovio Pharmaceuticals, Inc.

Inovio is developing a new generation of vaccines, called DNA
vaccines, to treat and prevent cancers and infectious diseases. Its
SynCon™ vaccines are designed to provide broad cross-strain
protection against known as well as newly emergent strains of
pathogens such as influenza. These vaccines, in combination with
Inovio’s proprietary electroporation delivery devices, have been
shown to be safe and generate significant immune responses. Inovio
clinical programs include three Phase II studies for vaccines
treating cervical dysplasia/cancer, hepatitis C virus, and
leukemia. Other clinical programs target influenza (preventive) and
HIV (preventive and therapeutic). Inovio partners and collaborators
include the University of Pennsylvania, Merck, ChronTech, National
Cancer Institute, U.S. Military HIV Research Program, NIH, HIV
Vaccines Trial Network, University of Southampton, and PATH Malaria
Vaccine

‘/>”/>

SOURCE